Year Founded
2021
Ownership
Private
Employees
~50
Stage
Preclinical
Modalities
RNA therapeutics

Exai Bio General Information

Developing a novel RNA-based liquid biopsy platform for early cancer detection using orphan non-coding RNAs (oncRNAs). Platform has been validated in multiple studies including I-SPY 2 trial for breast cancer.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

No pipeline data available

For full access to Exai Bio's pipeline data

Book a demo

Key Partnerships

UCSF

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Exai Bio Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Exai Bio's complete valuation and funding history, request access »

Exai Bio Investors

Section32
Investor Type: Venture Capital
Holding: Minority
Casdin Capital
Investor Type: Venture Capital
Holding: Minority
Bruker Corporation
Investor Type: Venture Capital
Holding: Minority